Merck, Inc.
🇵🇭Philippines
Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)
Completed
- Conditions
- Hepatitis C, ChronicHepatitis C
- Interventions
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2015-02-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1077
- Registration Number
- NCT00724295
MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-07-25
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1615
- Registration Number
- NCT00722371
A Study to Test the Tolerability of an Investigational Electroporation Device in Healthy Adults (V930-001)
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: V930
- First Posted Date
- 2008-07-24
- Last Posted Date
- 2015-08-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00721461
A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 121
- Registration Number
- NCT00717860
Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED)
Phase 3
Completed
- Conditions
- GastroenteritisRotavirus
- Interventions
- Biological: Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™)
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 762
- Registration Number
- NCT00718237
MK3207 for Treatment of Acute Migraines (3207-005)
Phase 2
Completed
- Conditions
- Migraine
- Interventions
- Drug: MK3207- 20 mgDrug: MK3207- 50 mgDrug: MK3207- 100 mgDrug: MK3207- 10 mgDrug: MK3207- 5 mgDrug: MK3207- 2.5 mg
- First Posted Date
- 2008-07-10
- Last Posted Date
- 2015-02-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 676
- Registration Number
- NCT00712725
Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243)
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Biological: PegIntron (peginterferon alfa-2b; SCH 54031)Drug: Rebetol (ribavirin; SCH 18908)
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 538
- Registration Number
- NCT00709059
Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 496
- Registration Number
- NCT00709228
Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)
Phase 3
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Biological: Pegylated interferon alfa-2b (SCH 54031)Drug: Boceprevir (SCH 503034)Drug: Ribavirin (SCH 18908)Drug: Boceprevir placebo
- First Posted Date
- 2008-07-02
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 404
- Registration Number
- NCT00708500
Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)
Phase 3
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2008-06-26
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1472
- Registration Number
- NCT00705432
© Copyright 2025. All Rights Reserved by MedPath